Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
J Ethnopharmacol ; 236: 108-113, 2019 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-30849503

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: According to traditional Korean medicine theory in which children's growth retardation is attributed to blood deficiency, Siwu decoction (SWD), a representative treatment for blood deficiency, was chosen as a sample. AIM OF THE STUDY: To evaluate the effects of SWD on chondrocyte proliferation of growth plate in adolescent female rats. MATERIALS AND METHODS: Female adolescent rats were allocated to one of the following four groups; SWD 100 and 300 mg/kg, recombinant human growth hormone, and vehicle for 4 days. Tetracycline was intraperitoneally injected at 48 h before sacrifice to obtain a band exhibiting fluorescence by binding newly formed bone. Bromodeoxyuridine was injected at day 2-4 to mark proliferating chondrocytes. To evaluate possible mechanisms of SWD, expressions of insulin-like growth factor-1 (IGF-1) and bone morphogenetic protein-2 (BMP-2) in the growth plate were examined by immunohistochemistry. RESULTS: Treatment with SWD significantly increased the number of BrdU-positive chondrocytes and the new bone formation in the proximal growth plate of tibia compared to the vehicle treated control group. SWD also increased the expression of IGF-1 and BMP-2 in the proliferative and hypertrophic zones of the growth plate. CONCLUSIONS: SWD 300 mg/kg stimulates chondrocyte proliferation and new bone formation in the growth plate. Immunohistochemical studies indicate that the effects of SWD may be due to upregulation of local IGF-1 and BMP-2 expression in the growth plate, which may be considered as a GH-dependent paracrine-autocrine pathway.


Asunto(s)
Desarrollo Óseo/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Condrocitos/efectos de los fármacos , Placa de Crecimiento/efectos de los fármacos , Extractos Vegetales/farmacología , Animales , Proteína Morfogenética Ósea 2/biosíntesis , Condrocitos/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Placa de Crecimiento/metabolismo , Factor I del Crecimiento Similar a la Insulina/biosíntesis , Medicina Tradicional Coreana , Ratas , Ratas Sprague-Dawley , Tibia/efectos de los fármacos , Tibia/metabolismo
2.
J Ethnopharmacol ; 213: 321-327, 2018 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-29191397

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Aconiti Sinomontani Radix is frequently used in the treatment of Bi syndrome in traditional Chinese medicine. Several reports indicate that Aconiti Sinomontani Radix has therapeutic effects for rheumatoid arthritis (RA). However, the cellular mode of action is still unclear. To investigate the effect of alkaloid extracts of Aconiti Sinomontani Radix on proliferation and migration of human synovial sarcoma SW982 cells as well as the molecular mechanism underlying. MATERIALS AND METHODS: SW982 cells were examined for proliferation by a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) method. Wound scratch assays were performed to assess the migrated rate of SW982 cells. Quantitative real-time PCR was used to measure the mRNA expression levels of Wnt5a, Runx2, MMP3, and Bmp2. Western blotting was used to measure the phosphorylated levels of JNK and NF-κB as well as the expression of MMP3. RESULTS: The alkaloid extract from Aconiti Sinomontani Radix (MQA) and MQB, which removed lappaconitine from MQA significantly inhibited the proliferation of SW982 in a dose-dependent manner. The proliferation inhibitory effect of MQB was more potent. Incubation with 10µg/ml MQB for 12, 24, and 36h inhibited the migration of SW982 cells by 83%, 58%, and 42%, respectively. Treatment with different concentrations of MQB for 24h inhibited mRNA expression of Wnt5a, Runx2, and MMP3, but Bmp2 mRNA expression was elevated by MQB. Further, MQB inhibited phosphorylation of JNK and NF-κB p65 as well as MMP3 expression by Western blotting analysis. CONCLUSION: The results showed that MQB inhibited proliferation and migration of SW982 cells possibly through suppressing Wnt5a-mediated JNK and NF-κB pathways. These results indicated that MQB might be an active extract of Aconiti Sinomontani Radix for targeting fibroblast-like synoviocytes (FLS) and be potential for RA therapy.


Asunto(s)
Aconitum/química , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Extractos Vegetales/farmacología , Sinoviocitos/citología , Sinoviocitos/efectos de los fármacos , Proteína Morfogenética Ósea 2/biosíntesis , Línea Celular , Ensayos de Migración Celular , Subunidad alfa 1 del Factor de Unión al Sitio Principal/biosíntesis , Relación Dosis-Respuesta a Droga , Fibroblastos/citología , Expresión Génica/efectos de los fármacos , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Metaloproteinasa 3 de la Matriz/biosíntesis , FN-kappa B/metabolismo , Fosforilación/efectos de los fármacos , Proteína Wnt-5a/biosíntesis
3.
Biomed Res Int ; 2017: 8619385, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28210626

RESUMEN

Expedited bone tissue engineering employs the biological stimuli to harness the intrinsic regenerative potential of skeletal muscle to trigger the reparative process in situ to improve or replace biological functions. When genetically modified with adenovirus mediated BMP2 gene transfer, muscle biopsies from animals have demonstrated success in regenerating bone within rat bony defects. However, it is uncertain whether the human adult skeletal muscle displays an osteogenic potential in vitro when a suitable biological trigger is applied. In present study, human skeletal muscle cultured in a standard osteogenic medium supplemented with dexamethasone demonstrated significant increase in alkaline phosphatase activity approximately 24-fold over control at 2-week time point. More interestingly, measurement of mRNA levels revealed the dramatic results for osteoblast transcripts of alkaline phosphatase, bone sialoproteins, transcription factor CBFA1, collagen type I, and osteocalcin. Calcified mineral deposits were demonstrated on superficial layers of muscle discs after an extended 8-week osteogenic induction. Taken together, these are the first data supporting human skeletal muscle tissue as a promising potential target for expedited bone regeneration, which of the technologies is a valuable method for tissue repair, being not only effective but also inexpensive and clinically expeditious.


Asunto(s)
Proteína Morfogenética Ósea 2/genética , Regeneración Ósea/genética , Músculo Esquelético/metabolismo , Osteogénesis/genética , Ingeniería de Tejidos , Adenoviridae/genética , Adulto , Fosfatasa Alcalina/biosíntesis , Fosfatasa Alcalina/genética , Animales , Proteína Morfogenética Ósea 2/biosíntesis , Diferenciación Celular/genética , Colágeno Tipo I/biosíntesis , Colágeno Tipo I/genética , Dexametasona/administración & dosificación , Femenino , Humanos , Sialoproteína de Unión a Integrina/biosíntesis , Sialoproteína de Unión a Integrina/genética , Masculino , Células Madre Mesenquimatosas/metabolismo , Persona de Mediana Edad , Músculo Esquelético/citología , Osteoblastos/efectos de los fármacos , Osteocalcina/biosíntesis , Osteocalcina/genética , Ratas
4.
Pharmacology ; 99(1-2): 67-74, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-27736819

RESUMEN

OBJECTIVE: The aim of the study was to explore the efficacy of Fu-Yuan Capsule in the healing of fractures of the lower end of the radius in a rabbit model. METHODS: After establishing a rabbit fracture model, all animals were randomly divided into the model group (n = 24), the Fu-Yuan Capsule group (n = 24), and the Shenyang Hongyao group (n = 24). The X-ray was applied to observe the course of fracture healing at 2, 4, 6, and 8 weeks after treatment. Haematoxylin-eosin staining and immunohistochemical staining were used to determine the histological change and the expression of bone morphogenetic protein-2 (BMP-2). Serum alkaline phosphatase (ALP), calcium, and phosphorus levels were detected before and after treatment. RESULTS: X-ray showed that the Fu-Yuan Capsule and Shenyang Hongyao groups exhibited abundant callus shadow areas than the model group in a time-dependent manner. In the model group, the fractures exhibited poor recovery with fibrous callus and obstructed bone marrow cavity. In the Fu-Yuan Capsule and Shenyang Hongyao groups, the fracture showed good recovery and restored normal structure with an effective remodeling of the lamellar bone. Immunohistochemical staining showed that the Fu-Yuan Capsule and Shenyang Hongyao groups had higher expressions of BMP-2 than the model group. Furthermore, serum ALP and calcium-phosphorus product in the Fu-Yuan Capsule and Shenyang Hongyao groups were higher than what they were in the model group. CONCLUSIONS: These results suggest that Fu-Yuan Capsule could promote the fracture healing through upregulating BMP-2 expression and increasing serum ALP and calcium-phosphorus product.


Asunto(s)
Medicamentos Herbarios Chinos/administración & dosificación , Curación de Fractura/efectos de los fármacos , Fracturas Óseas/diagnóstico por imagen , Fracturas Óseas/tratamiento farmacológico , Radio (Anatomía)/diagnóstico por imagen , Radio (Anatomía)/lesiones , Animales , Proteína Morfogenética Ósea 2/biosíntesis , Cápsulas , Femenino , Curación de Fractura/fisiología , Fracturas Óseas/metabolismo , Masculino , Conejos , Radio (Anatomía)/metabolismo , Resultado del Tratamiento
5.
Molecules ; 21(4): 461, 2016 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-27070559

RESUMEN

This study aimed to investigate the effects of Phlomis umbrosa root on bone growth and growth mediators in rats. Female adolescent rats were administered P. umbrosa extract, recombinant human growth hormone or vehicle for 10 days. Tetracycline was injected intraperitoneally to produce a glowing fluorescence band on the newly formed bone on day 8, and 5-bromo-2'-deoxyuridine was injected to label proliferating chondrocytes on days 8-10. To assess possible endocrine or autocrine/paracrine mechanisms, we evaluated insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) or bone morphogenetic protein-2 (BMP-2) in response to P. umbrosa administration in either growth plate or serum. Oral administration of P. umbrosa significantly increased longitudinal bone growth rate, height of hypertrophic zone and chondrocyte proliferation of the proximal tibial growth plate. P. umbrosa also increased serum IGFBP-3 levels and upregulated the expressions of IGF-1 and BMP-2 in growth plate. In conclusion, P. umbrosa increases longitudinal bone growth rate by stimulating proliferation and hypertrophy of chondrocyte with the increment of circulating IGFBP-3. Regarding the immunohistochemical study, the effect of P. umbrosa may also be attributable to upregulation of local IGF-1 and BMP-2 expressions in the growth plate, which can be considered as a GH dependent autocrine/paracrine pathway.


Asunto(s)
Desarrollo Óseo/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Tibia/efectos de los fármacos , Animales , Proteína Morfogenética Ósea 2/biosíntesis , Condrocitos/efectos de los fármacos , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Placa de Crecimiento/efectos de los fármacos , Placa de Crecimiento/crecimiento & desarrollo , Humanos , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/biosíntesis , Factor I del Crecimiento Similar a la Insulina/biosíntesis , Phlomis/química , Extractos Vegetales/química , Raíces de Plantas/química , Ratas , Tibia/crecimiento & desarrollo
6.
Mol Neurobiol ; 53(7): 4606-17, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-26307610

RESUMEN

Iodine deficiency (ID) during development results in dysfunction of the central nervous system (CNS) and affects psychomotor and motor function. It is worth noting that maternal mild and marginal ID tends to be the most common reason of preventable neurodevelopmental impairment, via a mechanism that has not been elucidated. Therefore, our aim was to study the effects of developmental mild and marginal ID on the differentiation of cerebellar granule cells (GCs) and investigate the activation of BMP-Smad1/5/8 signaling, which is crucial for the development and differentiation of cerebellum. Three developmental rat models were created by feeding dam rats with a diet deficient in iodine and deionized water supplemented with potassium iodide. Our results showed that different degrees of ID inhibited and delayed the differentiation of cerebellar GCs on postnatal day (PN) 7, PN14, and PN21. Moreover, mild and severe ID reduced the expression of BMP2 and p-Smad1/5/8, and increased the levels of Id2 on PN7, PN14, and PN21. However, marginal ID rarely altered expression of these proteins in the offspring. Our study supports the hypothesis that mild and severe ID during development inhibits the differentiation of cerebellar GCs, which may be ascribed to the down-regulation of BMP-Smad1/5/8 signaling and the overexpression of Id2. Furthermore, it was speculated that maternal marginal ID rarely affected the differentiation of cerebellar GCs in the offspring.


Asunto(s)
Proteína Morfogenética Ósea 2/biosíntesis , Diferenciación Celular/fisiología , Cerebelo/citología , Cerebelo/metabolismo , Yodo/deficiencia , Proteínas Smad Reguladas por Receptores/biosíntesis , Animales , Femenino , Ratas , Ratas Wistar , Transducción de Señal/fisiología , Proteína Smad1/biosíntesis , Proteína Smad5/biosíntesis , Proteína Smad8/biosíntesis
7.
Med Sci Monit ; 21: 1428-39, 2015 May 18.
Artículo en Inglés | MEDLINE | ID: mdl-25982481

RESUMEN

BACKGROUND: Statins have been reported to promote bone formation. However, taken orally, their bioavailability is low to the bones. Implant therapies require a local repair response, topical application of osteoinductive agents, or biomaterials that promote implant fixation. MATERIAL/METHODS: The present study evaluated the effect of a single local injection of simvastatin on screw fixation in an ovariectomized rat model of osteoporosis. RESULTS: Dual-energy X-ray absorptiometry, micro-computed tomography, histology, and biomechanical tests revealed that 5 and 10 mg simvastatin significantly improved bone mineral density by 18.2% and 22.4%, respectively (P<0.05); increased bone volume fraction by 51.0% and 57.9%, trabecular thickness by 16.4% and 18.9%, trabeculae number by 112.0% and 107.1%, and percentage of osseointegration by 115.7% and 126.3%; and decreased trabeculae separation by 34.1% and 36.6%, respectively (all P<0.01). Bone mineral apposition rate was significantly increased (P<0.01). Furthermore, implant fixation was significantly increased (P<0.05), and bone morphogenetic protein 2 (BMP2) expression was markedly increased. Local injection of a single dose of simvastatin also promoted angiogenesis. Vessel number, volume, thickness, surface area, and vascular volume per tissue volume were significantly increased (all P<0.01). Vascular endothelial growth factor (VEGF), VEGF receptor-2, von Willebrand factor, and platelet endothelial cell adhesion molecule-1 expression were enhanced. CONCLUSIONS: A single local injection of simvastatin significantly increased bone formation, promoted osseointegration, and enhanced implant fixation in ovariectomized rats. The underlying mechanism appears to involve enhanced BMP2 expression and angiogenesis in the target bone.


Asunto(s)
Densidad Ósea/efectos de los fármacos , Tornillos Óseos , Neovascularización Fisiológica/efectos de los fármacos , Oseointegración/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Simvastatina/uso terapéutico , Absorciometría de Fotón , Animales , Vasos Sanguíneos/efectos de los fármacos , Vasos Sanguíneos/ultraestructura , Proteína Morfogenética Ósea 2/biosíntesis , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Fémur/irrigación sanguínea , Fémur/cirugía , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Inyecciones Intralesiones , Osteoporosis Posmenopáusica/fisiopatología , Ovariectomía/efectos adversos , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/biosíntesis , Ratas , Ratas Sprague-Dawley , Simvastatina/administración & dosificación , Simvastatina/farmacología , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Receptor 2 de Factores de Crecimiento Endotelial Vascular/biosíntesis , Receptor 2 de Factores de Crecimiento Endotelial Vascular/genética , Factor de von Willebrand/biosíntesis
8.
Cell Tissue Res ; 356(2): 381-90, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24682582

RESUMEN

The proliferation and osteogenic capacity of mesenchymal stem cells (MSCs) needs to be improved for their use in cell-based therapy for osteoporosis. (-)-Epigallocatechin-3-gallate (EGCG), one of the green tea catechins, has been widely investigated in studies of osteoblasts and osteoclasts. However, no consensus on its role as an osteogenic inducer has been reached, possibly because of the various types of cell lines examined and the range of concentrations of EGCG used. In this study, the osteogenic effects of EGCG are studied in primary human bone-marrow-derived MSCs (hBMSCs) by detecting cell proliferation, alkaline phosphatase (ALP) activity and the expression of relevant osteogenic markers. Our results show that EGCG has a strong stimulatory effect on hBMSCs developing towards the osteogenic lineage, especially at a concentration of 5 µM, as evidenced by an increased ALP activity, the up-regulated expression of osteogenic genes and the formation of bone-like nodules. Further exploration has indicated that EGCG directes osteogenic differentiation via the continuous up-regulation of Runx2. The underlying mechanism might involve EGCG affects on osteogenic differentiation through the modulation of bone morphogenetic protein-2 expression. EGCG has also been found to promote the proliferation of hBMSCs in a dose-dependent manner. This might be associated with its antioxidative effect leading to favorable amounts of reactive oxygen species in the cellular environment. Our study thus indicates that EGCG can be used as a pro-osteogenic agent for the stem-cell-based therapy of osteoporosis.


Asunto(s)
Células de la Médula Ósea/citología , Catequina/análogos & derivados , Células Madre Mesenquimatosas/citología , Osteogénesis/efectos de los fármacos , Fosfatasa Alcalina/biosíntesis , Antioxidantes/farmacología , Proteína Morfogenética Ósea 2/biosíntesis , Catequina/farmacología , Diferenciación Celular/efectos de los fármacos , Linaje de la Célula , Proliferación Celular/efectos de los fármacos , Tratamiento Basado en Trasplante de Células y Tejidos , Subunidad alfa 1 del Factor de Unión al Sitio Principal/biosíntesis , Humanos , Osteogénesis/genética , Osteoporosis/terapia , Té/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/antagonistas & inhibidores
9.
J Tissue Eng Regen Med ; 8(10): 763-70, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22888035

RESUMEN

In the field of bone regeneration, BMP-2 is considered one of the most important growth factors because of its strong osteogenic activity, and is therefore extensively used in clinical practice. However, the short half-life of BMP-2 protein necessitates the use of supraphysiological doses, leading to severe side-effects. This study investigated the efficiency of bone formation at ectopic and orthotopic sites as a result of a low-cost, prolonged presence of BMP-2 in a large animal model. Constructs consisting of alginate hydrogel and BMP-2 cDNA, together acting as a non-viral gene-activated matrix, were combined with goat multipotent stromal cells (gMSCs) and implanted in spinal cassettes or, together with ceramic granules, intramuscularly in goats, both for 16 weeks. Bone formation occurred in all cell-seeded ectopic constructs, but the constructs containing both gMSCs and BMP-2 plasmid DNA showed higher collagen I and bone levels, indicating an osteogenic effect of the BMP-2 plasmid DNA. This was not seen in unseeded constructs, even though transfected, BMP-2-producing cells were detected in all constructs containing plasmid DNA. Orthotopic constructs showed mainly bone formation in the unseeded groups. Besides bone, calcified alginate was present in these groups, acting as a surface for new bone formation. In conclusion, transfection of seeded or resident cells from this DNA delivery system led to stable expression of BMP-2 during 16 weeks, and promoted osteogenic differentiation and subsequent bone formation in cell-seeded constructs at an ectopic location and in cell-free constructs at an orthotopic location in a large animal model.


Asunto(s)
Proteína Morfogenética Ósea 2 , ADN Complementario , Técnicas de Transferencia de Gen , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/metabolismo , Osteogénesis , Plásmidos , Alginatos/farmacología , Animales , Autoinjertos , Proteína Morfogenética Ósea 2/biosíntesis , Proteína Morfogenética Ósea 2/genética , Células Cultivadas , Células Inmovilizadas/metabolismo , Células Inmovilizadas/trasplante , ADN Complementario/genética , ADN Complementario/farmacología , Cabras , Hidrogeles/farmacología , Plásmidos/genética , Plásmidos/farmacología
10.
J Cell Biochem ; 114(8): 1720-8, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23386463

RESUMEN

A range of biological and molecular effects caused by nicotine are considered to effect bone metabolism. Vitamin C functions as a biological antioxidant. This study was to evaluate the in vitro effects of nicotine on human bone marrow stromal cells and whether Vitamin C supplementation show the antagonism action to high concentration nicotine. We used CCK-8, alkaline phosphatase (ALP) activity assay, Von Kossa staining, real-time polymerase chain reaction and Western Blot to evaluate the proliferation and osteogenic differentiation. The results indicated that the proliferation of BMSCs increased at the concentration of 50, 100 ng/ml, got inhibited at 1,000 ng/ml. When Vitamin C was added, the OD for proliferation increased. For ALP staining, we found that BMSCs treated with 50 and 100 ng/ml nicotine showed a higher activity compared with the control, and decreased at the 1,000 ng/ml. Bone morphogenetic protein-2 (BMP-2) expression and the calcium depositions decreased at 100 and 1,000 ng/ml nicotine, while the addition of Vitamin C reversed the down regulation. By real-time PCR, we detected that the mRNA expression of collagen type I (COL-I) and ALP were also increased in 50 and 100 ng/ml nicotine groups (P < 0.05), while reduced at 1,000 ng/ml (P < 0.05). When it came to osteocalcin (OCN), the changes were similar. Taken all together, it is found that nicotine has a two-phase effect on human BMSCs, showing that low level of nicotine could promote the proliferation and osteogenic differentiation while the high level display the opposite effect. Vitamin C could antagonize the inhibitory effect of higher concentration of nicotine partly.


Asunto(s)
Antioxidantes/farmacología , Ácido Ascórbico/farmacología , Células de la Médula Ósea/metabolismo , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Estimulantes Ganglionares/farmacología , Nicotina/farmacología , Osteogénesis/efectos de los fármacos , Adulto , Anciano , Ácido Ascórbico/antagonistas & inhibidores , Células de la Médula Ósea/citología , Proteína Morfogenética Ósea 2/biosíntesis , Células Cultivadas , Relación Dosis-Respuesta a Droga , Antagonismo de Drogas , Femenino , Estimulantes Ganglionares/antagonistas & inhibidores , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Nicotina/antagonistas & inhibidores , Células del Estroma/citología , Células del Estroma/metabolismo
11.
Osteoporos Int ; 23(11): 2649-60, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22535190

RESUMEN

UNLABELLED: The purpose of this study is to investigate the anti-osteoporotic effects of Radix Dipsaci total saponins (RTS). We showed that RTS was able to improve bone properties by either an increase of osteoblastic activity or a decrease in osteoclastic activity. INTRODUCTION: Radix Dipsaci has long been used as an anti-osteoporotic drug. The present study investigates the anti-osteoporotic effects of RTS. METHODS: Three-month-old female rats were randomly assigned into a sham-operated group (sham) and five ovariectomy (OVX) subgroups, namely, OVX with vehicle (OVX), OVX with 17ß-ethinylestradiol (E(2)), and OVX with graded doses of RTS (50, 100, or 200 mg/kg/d). RTS and E(2) were administered orally, daily from 1 week after OVX treatment for 4 months. Bone mass, turnover, and strength were evaluated by dual-energy X-ray absorptiometry, biochemical markers, and the three-point bending test. The trabecular bone microarchitecture was assessed by microCT. In vitro experiments were performed to determine the potential molecular mechanisms of the anti-osteoporotic effect of RTS. RESULTS: RTS prevented the loss of bone mass induced by OVX. The preventive effect on bone loss was primarily indicated by decreasing levels of bone turnover markers and confirmed by the changes in urinary calcium and phosphorus excretion. The treatment also enhanced the biomechanical strength of bone and prevented the deterioration of trabecular bone microarchitecture. RTS induced MC3T3-E1 and primary osteoblastic cell maturation and differentiation and increased bone formation by increasing BMP-2 synthesis. In addition, RTS inhibited osteoclastogenesis through an increase in osteoprotegrin and a decrease in NF-kB ligand expression in vitro. CONCLUSIONS: RTS treatment can effectively suppress the loss of bone mass induced by OVX and in vitro evidence suggests this could be through actions on both osteoblasts and osteoclasts.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Dipsacaceae , Medicamentos Herbarios Chinos/uso terapéutico , Osteoporosis/prevención & control , Saponinas/uso terapéutico , Animales , Peso Corporal/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Conservadores de la Densidad Ósea/farmacología , Proteína Morfogenética Ósea 2/biosíntesis , Calcio/metabolismo , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Medicamentos Herbarios Chinos/farmacología , Estradiol/uso terapéutico , Femenino , Fémur/diagnóstico por imagen , Fémur/fisiopatología , Tamaño de los Órganos/efectos de los fármacos , Osteoblastos/efectos de los fármacos , Osteoblastos/patología , Osteoclastos/efectos de los fármacos , Osteoclastos/patología , Osteoporosis/diagnóstico por imagen , Osteoporosis/patología , Osteoporosis/fisiopatología , Osteoprotegerina/biosíntesis , Ovariectomía , Fósforo/metabolismo , Ligando RANK/biosíntesis , Ratas , Ratas Sprague-Dawley , Saponinas/farmacología , Tomografía Computarizada por Rayos X , Regulación hacia Arriba/efectos de los fármacos , Útero/patología
12.
Biomed Mater ; 6(4): 045004, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21636885

RESUMEN

The bone morphogenetic protein 2 (BMP-2) gene delivery system with a gene-fibronectin (Fn)-apatite composite layer was fabricated on the surface of a hydroxyapatite ceramic scaffold. The BMP-2 gene-Fn-apatite composite layer was coated on the scaffold using a supersaturated calcium phosphate solution supplemented with BMP-2 DNA and Fn. The scaffolds were ectopically implanted into the dorsal subcutaneous tissue of rats. Four weeks after the implantation, the hydroxyapatite scaffold coated with the BMP-2 gene-Fn-apatite composite layer showed improved gene expressions of BMP-2 and alkaline phosphatase as compared with the scaffold coated with the apatite layer. Although these results suggest the possibility of ectopic bone formation induced by the present gene delivery system, further study is necessary to prove this.


Asunto(s)
Fosfatasa Alcalina/biosíntesis , Apatitas , Proteína Morfogenética Ósea 2/biosíntesis , Fibronectinas/química , Fosfatasa Alcalina/química , Animales , Biomarcadores/metabolismo , Proteína Morfogenética Ósea 2/química , ADN/química , Durapatita , Regulación de la Expresión Génica , Técnicas de Transferencia de Gen , Microscopía/métodos , Microscopía Electrónica de Rastreo/métodos , Ratas , Ratas Endogámicas F344 , Propiedades de Superficie
13.
Phytother Res ; 25(6): 922-6, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21394809

RESUMEN

Empirical evidence has shown that curculigoside, the main active compound of the traditionally used Chinese herb, Curculigo orchioides (Amaryllidaceae, rhizome), affects bone formation and fracture healing. However, the mechanistic details of these processes remain unclear. Therefore, the effects of curculigoside on immortalized, pre-osteoblastic mouse MC3T3-E1 cells was investigated. Following treatment with curculigoside, MC3T3-E1 cells exhibited an increased rate of proliferation. Higher levels of vascular endothelial growth factor (VEGF), Fms-like tyrosine kinase-1 (Flt-1) and bone morphogenetic protein-2 (BMP-2) were also detected in cell supernatants and cell lysates by ELISA and western blot analysis, respectively. Furthermore, the stimulatory effect of curculigoside was observed at relatively low doses (i.e. 10-100 µg/mL). In combination, these responses to treatment with curculigoside elucidate mechanistic details underlying the therapeutic effects of Curculigo orchioides on bone, and identifies these molecules as potential targets for the treatment of common metabolic bone diseases.


Asunto(s)
Benzoatos/farmacología , Glucósidos/farmacología , Osteoblastos/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Células 3T3 , Animales , Proteína Morfogenética Ósea 2/biosíntesis , Procesos de Crecimiento Celular/efectos de los fármacos , Curculigo/química , Medicamentos Herbarios Chinos/farmacología , Ratones , Osteoblastos/citología , Osteoblastos/metabolismo , Extractos Vegetales/farmacología , Rizoma/química , Regulación hacia Arriba/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/metabolismo , Receptor 1 de Factores de Crecimiento Endotelial Vascular/biosíntesis
14.
J Cell Biochem ; 112(3): 916-23, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21328465

RESUMEN

There has been a strong interest in searching for natural therapies for osteoporosis. Genistein, an isoflavone abundant in soy, and icariin, a prenylated flavonol glycoside isolated from Epimedium Herb, have both been identified to exert beneficial effects in preventing postmenopausal bone loss. However, the relative potency in osteogenesis between the individual phytoestrogen flavonoids remains unknown. The present study compared ability of genistein and icariin in enhancing differentiation and mineralization of cultured rat calvarial osteoblasts in vitro. Dose-dependent studies in osteoblast differentiation measuring alkaline phosphatase (ALP) activity revealed optimal concentrations of genistein and icarrin for stimulating osteogenesis to be both at 10(-5) M. Time course studies comparing the two compounds both at 10(-5) M demonstrated that icariin treatment always produced higher ALP activity, more and larger areas of CFU-F(ALP) colonies and mineralized nodules, more osteocalcin secretion, and calcium deposition, and a higher level of mRNA expression of osteogenesis-related genes COL1α2, BMP-2, OSX, and RUNX-2. However, they inhibited the proliferation of osteoblasts to a similar degree. In conclusion, although future in vivo studies are required to investigate whether icariin is more efficient in improving bone mass and/or preventing bone loss, our in vitro studies have demonstrated that icariin has a stronger osteogenic activity than genistein. In addition, while the prenyl group on C-8 of icariin could be the active group that takes part in osteoblastic differentiation and explains its greater potency in osteogenesis, mechanisms of action, and reasons for the relative potency of icariin versus genistein need to be further studied.


Asunto(s)
Calcificación Fisiológica/efectos de los fármacos , Medicamentos Herbarios Chinos/farmacología , Flavonoides/farmacología , Genisteína/farmacología , Osteoblastos/efectos de los fármacos , Fosfatasa Alcalina/metabolismo , Animales , Proteína Morfogenética Ósea 2/biosíntesis , Proteína Morfogenética Ósea 2/genética , Calcio/metabolismo , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Colágeno/biosíntesis , Colágeno/genética , Colágeno Tipo I , Subunidad alfa 1 del Factor de Unión al Sitio Principal/biosíntesis , Subunidad alfa 1 del Factor de Unión al Sitio Principal/genética , Pruebas de Enzimas , Osteoblastos/citología , Osteoblastos/metabolismo , Osteocalcina/metabolismo , ARN Mensajero/biosíntesis , Ratas , Ratas Wistar , Cráneo/citología , Factores de Transcripción/biosíntesis , Factores de Transcripción/genética
15.
Bull Mem Acad R Med Belg ; 166(7-9): 307-15; discussion 316, 2011.
Artículo en Francés | MEDLINE | ID: mdl-22891446

RESUMEN

The discovery of the dynamic electrical properties of bone is at the origin of the therapeutical application of the electromagnetic fields in Orthopaedics and Traumatology. The first empirical treatment of non-union, fresh fractures and osteonecroses allowed the observation of several effects which, without justifying a systematic clinical application, encouraged further fundamental research. The results of this work realized during 35 years are summarized in the present article. After exposure to specific electromagnetic fields, we observed a modification of the DNA activity and an increased production of RNA. During enchondral ossification, the amount of acid GAGS increased faster and the ossification of the primary ossification point is accelerated. On fresh fractures, the rigidity of the callus increased faster. Finally, the microarrays analyses show an upregulation of mRNA involved in cellular differentiation and proliferation. The mRNA responsible of the production of BMP-2 is significantly increased, explaining the main results observed after the expense of experimental models of the bond tissues. All the observed results are in favour of an acceleration of the cellular differentiation at the expense of the proliferation.


Asunto(s)
Terapia por Estimulación Eléctrica , Campos Electromagnéticos , Fracturas no Consolidadas/terapia , Osteonecrosis/terapia , Animales , Proteína Morfogenética Ósea 2/biosíntesis , Proteína Morfogenética Ósea 2/efectos de la radiación , Diferenciación Celular/efectos de la radiación , Proliferación Celular/efectos de la radiación , ADN/efectos de la radiación , Curación de Fractura , Humanos , Modelos Biológicos , Osteogénesis/efectos de la radiación , ARN Mensajero/efectos de la radiación
16.
Eur Cell Mater ; 20: 403-14, 2010 Dec 13.
Artículo en Inglés | MEDLINE | ID: mdl-21154246

RESUMEN

Platelet-rich preparations have recently gained popularity in maxillofacial and dental surgery, but their beneficial effect is still under debate. Furthermore, very little is known about the effect of platelet preparations at the cellular level, and the underlying mechanisms. In this study, we tested the effect of platelet-released supernatant (PRS) on human mesenchymal stem cell (MSC) differentiation towards an osteoblastic phenotype in vitro. Cultures of MSC were supplemented with PRS and typical osteoblastic markers were assessed at up to 28 days post-confluence. PRS showed an osteoinductive effect on MSC, as shown by an increased expression of typical osteoblastic marker genes such as collagen Ialpha1, bone sialoprotein II, BMP-2 and MMP-13, as well as by increased 45Ca²+ incorporation. Our results suggest that the effect of PRS on human MSC could be at least partially mediated by BMP-2. Activated autologous PRS could therefore provide an alternative to agents like recombinant bone growth factors by increasing osteoblastic differentiation of bone precursor cells at bone repair sites, although further studies are needed to fully support our observations.


Asunto(s)
Factores Biológicos/sangre , Plaquetas/metabolismo , Proteína Morfogenética Ósea 2/biosíntesis , Células Madre Mesenquimatosas/citología , Osteoblastos/citología , Adulto , Anciano , Calcio/metabolismo , Diferenciación Celular , Células Cultivadas , Femenino , Perfilación de la Expresión Génica , Marcadores Genéticos , Humanos , Masculino , Células Madre Mesenquimatosas/fisiología , Persona de Mediana Edad , Fracciones Subcelulares/metabolismo
17.
J Endod ; 36(4): 647-52, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20307738

RESUMEN

INTRODUCTION: Mineral trioxide aggregate (MTA) is a therapeutic, endodontic repair material that is reported to exhibit calcified tissue-conductive activity although the mechanisms remain unclear. We hypothesize that the dissolution of calcium from MTA into the surrounding environment may play an important role in the osteoblastic/cementoblastic differentiation of human periodontal ligament cells (HPLCs). METHODS: Two populations of HPLCs were obtained from two patients, respectively, and were cultured in the presence or absence of MTA discs and/or CaCl(2) in order to investigate calcium release, calcification activity, calcium-sensing receptor (CaSR) gene expression and bone morphogenetic protein-2 (BMP-2), and BMP-2 receptor protein and gene expression. RESULTS: MTA released a substantial accumulation of calcium (4 mmol/L) within 14 days into culture media. After 4 weeks, the two populations of HPLCs independently exhibited calcification as well as BMP-2 distribution in the vicinity of MTA. HPLCs inherently expressed genes encoding for the CaSR and BMP-2 receptors. Exogenous CaCl(2) media supplementation induced CaSR gene expression in HPLCs and calcification and BMP-2 synthesis throughout the entire HPLC cultures, whereas MgCl(2) had no effect. Both MTA and CaCl(2) stimulated BMP-2 gene expression above that of baseline levels. CONCLUSION: Here we show the first report showing that HPLCs cocultured directly with MTA up-regulated BMP2 expression and calcification. These results may be through CaSR interactions that were potentially activated by the release of calcium from MTA into the culture environment.


Asunto(s)
Compuestos de Aluminio/farmacología , Proteína Morfogenética Ósea 2/biosíntesis , Compuestos de Calcio/farmacología , Óxidos/farmacología , Ligamento Periodontal/efectos de los fármacos , Ligamento Periodontal/metabolismo , Materiales de Obturación del Conducto Radicular/farmacología , Silicatos/farmacología , Calcificación de Dientes/efectos de los fármacos , Adolescente , Compuestos de Aluminio/metabolismo , Calcio/metabolismo , Cloruro de Calcio/farmacología , Compuestos de Calcio/metabolismo , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Cementogénesis/efectos de los fármacos , Técnicas de Cocultivo , Cemento Dental/citología , Combinación de Medicamentos , Femenino , Expresión Génica/efectos de los fármacos , Humanos , Masculino , Osteoblastos/citología , Osteogénesis/efectos de los fármacos , Óxidos/metabolismo , Ligamento Periodontal/citología , Receptores Sensibles al Calcio/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Materiales de Obturación del Conducto Radicular/metabolismo , Silicatos/metabolismo , Adulto Joven
18.
J Neurosci ; 30(11): 4062-71, 2010 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-20237276

RESUMEN

GABAergic dysfunction is implicated in a variety of neurodevelopmental and psychiatric disorders. The mechanisms underlying GABAergic differentiation, however, are not well understood. GABA transporter 1 (Gat1; Slc6a1) is an essential component of the GABAergic system, and its ectopic mRNA expression may be responsible for GABAergic malfunction under different pathological conditions. Thus, monitoring the transcriptional regulation of gat1 may help to elucidate the mechanisms that govern the differentiation of GABAergic neurons. In this study, we identified a promoter region that is sufficient to recapitulate endogenous gat1 expression in transgenic mice. A 46 bp cis-regulator in the promoter sequence was responsible for the stimulation of bone morphogenetic protein-2 (BMP2) on gat1 expression in cortical cortex. Furthermore, our study demonstrated that Smad4 and YY1 are physically bound to the element and mediate both the negative and positive regulatory effects in which BMP2 can affect the balance. In summary, we have identified a Smad4/YY1-based bidirectional regulation model for GABAergic gene transcription and demonstrated a molecular cue important for the differentiation of GABAergic neurons.


Asunto(s)
Proteína Morfogenética Ósea 2/genética , Proteínas Transportadoras de GABA en la Membrana Plasmática/genética , Regiones Promotoras Genéticas/fisiología , Secuencias Reguladoras de Ácidos Nucleicos/genética , Proteína Smad4/genética , Factor de Transcripción YY1/genética , Animales , Proteína Morfogenética Ósea 2/antagonistas & inhibidores , Proteína Morfogenética Ósea 2/biosíntesis , Línea Celular Tumoral , Células Cultivadas , Corteza Cerebral/fisiología , Regulación hacia Abajo/genética , Proteínas Transportadoras de GABA en la Membrana Plasmática/metabolismo , Proteínas Transportadoras de GABA en la Membrana Plasmática/fisiología , Ratones , Ratones Transgénicos , Células 3T3 NIH , Unión Proteica/genética , Secuencias Reguladoras de Ácidos Nucleicos/fisiología , Proteína Smad4/metabolismo , Proteína Smad4/fisiología , Regulación hacia Arriba/genética , Factor de Transcripción YY1/metabolismo , Factor de Transcripción YY1/fisiología
19.
Am J Physiol Endocrinol Metab ; 296(1): E139-46, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19001547

RESUMEN

AMP-activated protein kinase (AMPK) and Rho kinase (ROK) are known to modulate the mevalonate pathway. Activation of AMPK suppresses 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase. ROK acts downstream of HMG-CoA reductase, and its inhibition exerts antiatherosclerosis effects. However, whether or not these enzymes are involved in bone metabolism is unclear. The present study was undertaken to investigate the effects of an AMPK activator, 5-aminoimidazole-4-carboxamide1-beta-d-ribonucleoside (AICAR), and a ROK inhibitor, fasudil hydrochrolide, on the mineralization of osteoblastic MC3T3-E1 cells. Real-time PCR and mineralization stainings revealed that both AICAR and fasudil significantly stimulated endothelial nitric oxide synthase (eNOS), bone morphogenetic protein-2 (BMP-2), and osteocalcin mRNA expression as well as mineralization in the cells. Supplementation of either mevalonate or geranyl-geranyl pyrophosphate, the downstream molecules of HMG-CoA reductase, or coincubation with either a nitric oxide synthase inhibitor, N(G)-nitro-l-arginine methyl ester, or a BMP-2 antagonist, noggin, significantly reversed these AICAR-induced reactions. Western blot analysis showed that AICAR activated protein kinase B and extracellular signal-regulated kinase (ERK). ERK inhibitor significantly reversed the AICAR-induced increase in eNOS and BMP-2 mRNA expression. Measurement of ROK activities by enzyme-linked immunosorbent assay revealed that both AICAR and fasudil significantly suppressed the phosphorylation of the myosin-binding subunit of myosin phosphate, a ROK substrate. These findings suggest that the AMPK activator and the ROK inhibitor are able to stimulate the mineralization of osteoblasts through modulating the mevalonate pathway. These agents could be candidate drugs that promote bone formation for the treatment of osteoporosis.


Asunto(s)
Adenilato Quinasa/metabolismo , Proteína Morfogenética Ósea 2/biosíntesis , Osteoblastos/metabolismo , Quinasas Asociadas a rho/antagonistas & inhibidores , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/análogos & derivados , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/farmacología , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/farmacología , Animales , Proteína Morfogenética Ósea 2/genética , Remodelación Ósea/efectos de los fármacos , Proteínas Portadoras/farmacología , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Línea Celular , Activación Enzimática , Histocitoquímica , Ratones , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa de Tipo III/biosíntesis , Óxido Nítrico Sintasa de Tipo III/genética , Osteoblastos/efectos de los fármacos , Osteoblastos/enzimología , Osteocalcina/genética , Osteocalcina/metabolismo , ARN Mensajero/química , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Ribonucleótidos/farmacología , Quinasas Asociadas a rho/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA